Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man
Name:
s41591-023-02318-3.pdf
Size:
9.608Mb
Format:
PDF
Description:
Final Published Version
Author
Lopera, F.Marino, C.
Chandrahas, A.S.
O’Hare, M.
Villalba-Moreno, N.D.
Aguillon, D.
Baena, A.
Sanchez, J.S.
Vila-Castelar, C.
Ramirez, Gomez, L.
Chmielewska, N.
Oliveira, G.M.
Littau, J.L.
Hartmann, K.
Park, K.
Krasemann, S.
Glatzel, M.
Schoemaker, D.
Gonzalez-Buendia, L.
Delgado-Tirado, S.
Arevalo-Alquichire, S.
Saez-Torres, K.L.
Amarnani, D.
Kim, L.A.
Mazzarino, R.C.
Gordon, H.
Bocanegra, Y.
Villegas, A.
Gai, X.
Bootwalla, M.
Ji, J.
Shen, L.
Kosik, K.S.
Su, Y.
Chen, Y.
Schultz, A.
Sperling, R.A.
Johnson, K.
Reiman, E.M.
Sepulveda-Falla, D.
Arboleda-Velasquez, J.F.
Quiroz, Y.T.
Affiliation
University of ArizonaIssue Date
2023-05-15
Metadata
Show full item recordPublisher
Nature ResearchCitation
Lopera, F., Marino, C., Chandrahas, A.S. et al. Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man. Nat Med 29, 1243–1252 (2023). https://doi.org/10.1038/s41591-023-02318-3Journal
Nature MedicineRights
© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
We characterized the world’s second case with ascertained extreme resilience to autosomal dominant Alzheimer’s disease (ADAD). Side-by-side comparisons of this male case and the previously reported female case with ADAD homozygote for the APOE3 Christchurch (APOECh) variant allowed us to discern common features. The male remained cognitively intact until 67 years of age despite carrying a PSEN1-E280A mutation. Like the APOECh carrier, he had extremely elevated amyloid plaque burden and limited entorhinal Tau tangle burden. He did not carry the APOECh variant but was heterozygous for a rare variant in RELN (H3447R, termed COLBOS after the Colombia–Boston biomarker research study), a ligand that like apolipoprotein E binds to the VLDLr and APOEr2 receptors. RELN-COLBOS is a gain-of-function variant showing stronger ability to activate its canonical protein target Dab1 and reduce human Tau phosphorylation in a knockin mouse. A genetic variant in a case protected from ADAD suggests a role for RELN signaling in resilience to dementia. © 2023, The Author(s).Note
Open access articleISSN
1078-8956PubMed ID
37188781Version
Final Published Versionae974a485f413a2113503eed53cd6c53
10.1038/s41591-023-02318-3
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License.